 AUSTIN, Texas, May 26, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and tumor-informed molecular residual disease MRD assay, Signatera, at the 2021 American Society of Clinical Oncology ASCO annual meeting, taking place June 4-8, 2021. Two additional studies were presented at the 2021 American Association for Cancer Research AACR annual meeting that took place April 9-14, 2021. 